2. Forward-Looking Statement
The statements in this presentation that are not historical facts are forward-looking statements based on current
expectations of future events and are subject to risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. In particular, the statements in this
presentation regarding clinical data and/or the regulatory status of our pipeline products are based on a
preliminary analysis of the data and our expectations as to how that data will impact the regulatory approval
process, which is subject to risks and uncertainties related to both the timing and success of regulatory
approval. In addition, although it remains our goal to resolve the issues raised in the Warning Letter relating to
our Guayama, Puerto Rico facility as quickly as possible, we cannot exclude the possibility that these issues
will result in further regulatory action or delays in the approval of new products or release of approved products
manufactured at the facility. Other risks and uncertainties include the inherent uncertainty of the timing and
success of, and expense associated with, research, development, regulatory approval and commercialization
of our products, including with respect to our pipeline products; government cost-containment initiatives;
restrictions on third-party payments for our products; substantial competition in our industry, including from
branded and generic products; data generated on our products; the importance of strong performance from our
principal products and our anticipated new product introductions; the highly regulated nature of our business;
product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding
our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with
respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions
including interest and currency exchange rate fluctuations; changes in generally accepted accounting
principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties
associated with global operations and sales; and other risks and uncertainties, including those detailed from
time to time in our periodic reports filed with the Securities and Exchange Commission, including our current
reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the
discussion under the caption “Item 1A, Risk Factors.” The forward-looking statements in this presentation are
qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or otherwise.
3. 1st Quarter 2007 – Key Financial Elements*
Net Revenue +11%
Gross Margin 73.1%
SG&A Expenses +3%
R&D Expense +10%
Operating Profit +22%
Tax Rate 28%
Diluted Earnings Per Share +12%
*Adjusted to Exclude Certain Significant Items
See Press Release Issued April 19, 2007
4. Net Revenue Growth
Total Wyeth Revenue Increased 11%
Pharmaceutical Revenue +11%
Consumer Healthcare Revenue +10%
Animal Health Revenue +11%
6. Pristiq™ for Vasomotor Symptoms
Previous FDA Action Date – April 23, 2007
n
Submitted Results From Study of 100 mg and 150 mg
n
Doses With Three-day 50 mg Titration
4Markedly Reduced Incidence of Nausea and Adverse Event Related
Discontinuations
4Confirmed Efficacy of the 100 mg and 150 mg Doses
Next Steps
n
4FDA Extended Review Cycle by Three Months to Late July
4Preparing for a U.S. Launch in the 3rd Quarter 2007
4New Data Will Also Be Submitted to European Regulatory Authorities
7. Pristiq™ for Depression
Approvable Letter – January 22, 2007
n
Excellent Results Achieved With Low Dose Studies
n
4Demonstrated Efficacy at 50 mg Dose
4Replicated Efficacy at 100 mg Dose
4Reduction in Adverse Event Related Discontinuation Rates
4Substantial Improvement in Nausea Rates and Overall Tolerability
Next Steps
n
4Submit Complete Response Letter by End of August 2007
- Allows for Processing of Final Clinical Reports and Integration of Data Into
Overall Safety and Efficacy Analyses
4Expect Six Month Extension to Review Cycle to 1st Quarter 2008
4Preparing for Launch Shortly After Approval
8. Lybrel™ for Contraception
FDA Action Date – May 2007
n
Anticipate Approval for Contraception With A
n
Continuous Regimen … Potential to Eliminate
Menstrual Bleeding
4Relief of Cycle Related Symptoms Will Not Be Included in This Initial
Approval
Next Steps
n
4Preparing for a U.S. Launch by Mid-Year 2007
4Mutual Recognition Procedure for European Approval Underway
9. Viviant™ for Osteoporosis Prevention
FDA Action Date – April 23, 2007
n
4Expect FDA to Issue an Approvable Letter
Three Year Fracture Study Completed
n
4Significant Reduction in the Incidence of Vertebral Fractures
4Significant Increase in Bone Mineral Density
4Reinforced Favorable Safety Profile
Next Steps
n
4Submission of Three Year Fracture Study by Mid-2007
4Expect Six Month Extension to Review Cycle to Year-End 2007
4European Filing for Osteoporosis Prevention and Treatment Planned for
Later in 2007
4U.S. Submission for Osteoporosis Treatment Planned for Later in 2007
10. Aprela™ for Osteoporosis and Vasomotor
Symptoms
FDA Filing Planned for Year-End 2007
n
Completed Another Phase 3 Clinical Trial
n
4Confirmed High Degree of Efficacy in Treating Vasomotor Symptoms
4Pleased With Safety Results for Breast and Endometrium
4Favorable Overall Tolerability Profile
11. Other Products Pending FDA Review
Bifeprunox
n
4Filed for Schizophrenia with FDA in October 2006
4Review is Ongoing and Tracking Towards the August Action Date
Methylnaltrexone
n
4Subcutaneous Formulation for the Treatment of Opioid-Induced
Constipation in Patients Receiving Palliative Care Filed With FDA in March
2007
Torisel™
n
4Additional Analyses on Tumor Progression Submitted to FDA
- Analyses Did Not Involve the Primary Endpoint of Overall Survival
4Review Cycle for Renal Cell Cancer Extended to July 2007 … Approval
Expected
12. Upcoming Filings
Tygacil ®
n
4Community Acquired and Hospital Acquired Pneumonia Studies Being
Analyzed
4On Track for Mid-Year Filing
Prevnar 13
n
4Infant and Adult Phase 3 Programs Underway
4Progressing Towards Planned 2009 Filings
13. Summary
Another Excellent Quarter for Wyeth
n
4 All Businesses Showed Strong Growth
Enbrel and Prevnar Were Strong Contributors
n
Continue to Work Towards a Timely Resolution of FDA’s Concerns
n
Regarding the Guayama Facility and We Do Not See Any Impact on the
Timing of Our New Product Launches
Received Important New Clinical Results for Several Late Stage Pipeline
n
Products
The Recently Completed Studies on Pristiq, Viviant and Aprela Will
n
Significantly Contribute to the Approval, Initial Positioning and Profiling
of These New Products
